Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
Original Research
,
Cardiometabolic Health
Can Academic Detailing Move the Needle for Patients with Diabetes in a State-Based Prescription Drug Benefit Program?
Dominick P. Trombetta, PharmD, BCPS, BCGP; Debra A. Heller, PhD, MPH
Read More
Perspectives
Pharmacy Integration
David B. Nash, MD, MBA
Read More
Original Research
,
Practice Management
The Economic Value of Customized versus Off-the-Shelf Knee Implants in Medicare Fee-for-Service Beneficiaries
Mary I. O’Connor, MD; Brittany E. Blau, MPH
Read More
FDA Approvals
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Read More
FDA Approvals
,
In the News
April 16, 2019 – FDA Approvals, News & Updates
Read More
FDA Approvals
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Read More
FDA Approvals
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Read More
FDA Approvals
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Read More
FDA Approvals
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Read More
FDA Approvals
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Read More
51
52
53
54
55
56
57
Page 54 of 244
Results 531 - 540 of 2434